Moneycontrol.com·2 min read·medium
Not practical to shift generic drug manufacturing to US: Dr Reddy's CEO on Trump's tariff plan
✦AI Summary
Dr. Reddy's CEO has stated that shifting generic drug manufacturing to the United States is not a practical solution in response to proposed tariff plans. The executive highlights the logistical and economic challenges of relocating complex pharmaceutical supply chains.
You are using an outdated browser. Please upgrade your browser to improve your experience and security.
businesseconomyhealth
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in